Pfizer (NYSE:PFE) Shares Up 0.9%

Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price was up 0.9% during trading on Friday . The stock traded as high as $25.66 and last traded at $25.62. Approximately 10,092,678 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 42,027,188 shares. The stock had previously closed at $25.39.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PFE shares. TD Cowen lowered shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They set a "buy" rating and a $36.00 price target for the company. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $36.88.

Pfizer Trading Up 2.4 %

The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a market capitalization of $147.17 billion, a price-to-earnings ratio of 72.19, a price-to-earnings-growth ratio of 1.15 and a beta of 0.61. The business's 50 day simple moving average is $27.11 and its 200 day simple moving average is $28.68.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the business posted $1.14 earnings per share. The business's revenue was down 41.3% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Institutional Trading of Pfizer

A number of institutional investors have recently added to or reduced their stakes in PFE. Everett Harris & Co. CA boosted its stake in Pfizer by 22.7% in the 1st quarter. Everett Harris & Co. CA now owns 144,722 shares of the biopharmaceutical company's stock worth $4,016,000 after buying an additional 26,812 shares during the last quarter. American National Bank & Trust Co. VA acquired a new stake in Pfizer in the first quarter valued at $285,000. FCG Investment Co grew its position in shares of Pfizer by 55.0% in the 1st quarter. FCG Investment Co now owns 17,848 shares of the biopharmaceutical company's stock worth $495,000 after acquiring an additional 6,333 shares in the last quarter. New Century Financial Group LLC acquired a new stake in Pfizer during the first quarter worth about $1,178,000. Finally, Fruth Investment Management grew its stake in Pfizer by 7.2% during the 1st quarter. Fruth Investment Management now owns 29,598 shares of the biopharmaceutical company's stock worth $821,000 after buying an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.